The estimated Net Worth of Gary Loeb is at least $2.45 million dollars as of 9 September 2024. Mr. Loeb owns over 300 units of Sangamo Therapeutics Inc stock worth over $1,340 and over the last 12 years he sold SGMO stock worth over $407,776. In addition, he makes $2,043,020 as Executive Vice President, Chief Compliance Officer, General Counsel et Secretary at Sangamo Therapeutics Inc.
Sign up
Mr. Loeb SGMO stock SEC Form 4 insiders trading
Gary has made over 9 trades of the Sangamo Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 300 units of SGMO stock worth $142,500 on 9 September 2024.
The largest trade he's ever made was selling 17,524 units of Sangamo Therapeutics Inc stock on 23 March 2021 worth over $230,090. On average, Gary trades about 1,117 units every 126 days since 2013. As of 9 September 2024 he still owns at least 1,595 units of Sangamo Therapeutics Inc stock.
You can see the complete history of Mr. Loeb stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gary Loeb biography
Gary H. Loeb serves as Executive Vice President, Chief Compliance Officer, General Counsel, Secretary of the Company. He has served as our Executive Vice President and General Counsel since July 2019 and as our Secretary and Chief Compliance Officer since September 2019. Mr. Loeb is responsible for all legal matters for Sangamo and has over 20 years of experience in biotechnology, legal transactions and operations, and compliance. Prior to joining Sangamo, Mr. Loeb served from November 2016 to June 2019 as General Counsel, Corporate Secretary and Chief Compliance Officer at Achaogen Inc., an anti-infectives company. As a member of the Executive Team, he built Achaogen’s legal and compliance functions and supported its first product launch for plazomicin, which is listed by the World Health Organization as an “essential medicine.” In April 2019, Achaogen filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code and most of its assets were subsequently sold to a multinational pharmaceutical company. Prior to joining Achaogen, Mr. Loeb served as General Counsel for Sano Intelligence Inc., a medical device company from November 2015 to June 2016, and as Executive Vice President, Business Development and General Counsel of Counsyl, Inc., a health technology company, from August 2013 to November 2015. Prior to Counsyl, Mr. Loeb was General Counsel at Amyris, Inc., a publicly-traded synthetic biotechnology company and Vice President of Intellectual Property at Genentech, Inc, where he was had roles of increasing responsibility over eleven years. Mr. Loeb received his B.S. and B.A. degrees from Stanford University and his J.D. from Columbia Law School.
What is the salary of Gary Loeb?
As the Executive Vice President, Chief Compliance Officer, General Counsel et Secretary of Sangamo Therapeutics Inc, the total compensation of Gary Loeb at Sangamo Therapeutics Inc is $2,043,020. There are 2 executives at Sangamo Therapeutics Inc getting paid more, with Alexander Macrae having the highest compensation of $3,986,560.
How old is Gary Loeb?
Gary Loeb is 50, he's been the Executive Vice President, Chief Compliance Officer, General Counsel et Secretary of Sangamo Therapeutics Inc since 2019. There are 13 older and 5 younger executives at Sangamo Therapeutics Inc. The oldest executive at Sangamo Therapeutics Inc is H. Stewart Parker, 64, who is the Independent Director.
What's Gary Loeb's mailing address?
Gary's mailing address filed with the SEC is 1020, Kifer Road, Sunnyvale, Santa Clara County, California, 94086, United States.
Insiders trading at Sangamo Therapeutics Inc
Over the last 24 years, insiders at Sangamo Therapeutics Inc have traded over $87,969,621 worth of Sangamo Therapeutics Inc stock and bought 3,434,008 units worth $48,483,268 . The most active insiders traders include Capital Management, L.P.Ra ..., Le Roy C Kopp et Inc.Biogen Ma Inc. Biogen. On average, Sangamo Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $40,671. The most recent stock trade was executed by Inc.Biogen Ma Inc. Biogen on 26 September 2023, trading 6,000,000 units of SGMO stock currently worth $3,000,000.
What does Sangamo Therapeutics Inc do?
for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.
What does Sangamo Therapeutics Inc's logo look like?
Complete history of Mr. Loeb stock trades at Amyris Inc, Intuitive Surgical Inc et Sangamo Therapeutics Inc
Sangamo Therapeutics Inc executives and stock owners
Sangamo Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Alexander Macrae,
President, Chief Executive Officer, Director -
Sung Lee,
Chief Financial Officer, Executive Vice President -
Gary Loeb,
Executive Vice President, Chief Compliance Officer, General Counsel, Secretary -
Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.,
CEO, Pres & Director -
R. Andrew Ramelmeier,
Executive Vice President - Technical Operations -
Dr. R. Andrew Ramelmeier Ph.D.,
Exec. VP of Technical Operations -
D. Mark McClung,
Exec. VP & COO -
James Meyers,
Independent Director -
H. Stewart Parker,
Independent Director -
Joseph Zakrzewski,
Independent Director -
Robert Carey,
Independent Director -
Saira Ramasastry,
Independent Director -
Karen Smith,
Independent Director -
McDavid Stilwell,
IR Contact Officer -
John Markels,
Independent Director -
Kenneth Hillan,
Director -
Prathyusha Duraibabu,
Vice President - Finance -
D. Mark McClung,
Executive Vice President, Chief Business Officer -
Scott B. Willoughby,
Sr. VP, Gen. Counsel & Corp. Sec. -
Prathyusha Duraibabu CPA, M.B.A.,
Sr. VP, CFO & Principal Accounting Officer -
Dr. Jason D. Fontenot Ph.D.,
Sr. VP & Chief Scientific Officer -
Prathyusha Duraibabu,
VP of Fin., Principal Accounting Officer & Principal Financial Officer -
Dr. Duncan McKay,
Sr. VP & GM of Europe -
Heather Erickson,
Chief of Staff -
Dr. Nathalie Dubois-Stringfellow,
Sr. VP of Product Devel. & Management -
Whitney Jones,
Sr. VP & Chief People Officer -
Aron Feingold,
Head of Corp. Communications & Investor Relations Officer -
Dr. Jason Fontenot Ph.D.,
Sr. VP & Chief Scientific Officer -
Stephen George Dilly,
Director -
Paul B Cleveland,
Director -
Henry Ward Wolff,
Director -
Steven J Mento,
Director -
William R Ringo,
Director -
Geoffrey Nichol,
Executive Vice President, R&D -
Curt A. Iii Herberts,
Sr.VP & Chief Business Officer -
Dale G Ando,
VP, Therapeutic Dev. & CMO -
Edward R. Conner,
Sr. VP & Chief Medical Officer -
Thomas G Wiggans,
Director -
William G Gerber,
Director -
Roger Jeffs,
Director -
Heather D Turner,
EVP, General Counsel & Sec. -
Robert J. Schott,
SVP, Head of Development -
Stephane Boissel,
EVP, Corp. Strategy -
Kathy Yi,
EVP & Chief Financial Officer -
Margaret Liu,
Director -
Michael C Wood,
Director -
Greg Zante,
Sr Dir., Finance and Admin -
Le Roy C Kopp,
10% owner -
Edward O Ii Lanphier,
President and CEO -
Jon E M Jacoby,
Director -
Casey C Case,
Vice President, Research -
Peter Bluford,
V.P., Corporate Development -
William J Rutter,
Director -
John William Larson,
Director -
Philip D Gregory,
Vice President, Research -
Capital Management, L.P.Ra ...,
-
David G Ichikawa,
Senior VP, Bus. Dev. -
Jason D. Fontenot,
SVP, Chief Scientific Officer -
Scott B. Willoughby,
SVP, GEN. COUNSEL & SECRETARY -
Inc.Biogen Ma Inc. Biogen,
-
Sandy Macrae,
PRESIDENT, CEO AND DIRECTOR -
Nathalie Dubois Stringfellow,
SVP-CHIEF DEVELOPMENT OFFICER -
Amy Pooler,
VP, HEAD OF RESEARCH -
Courtney Beers,
-
Margaret A Horn,